Department of Ophthalmology, Päijät-Häme Central Hospital, Lahti, Finland.
J Glaucoma. 2012 Jan;21(1):7-11. doi: 10.1097/IJG.0b013e3181fc8039.
To evaluate the outcome of 40 consecutive patients with Molteno3 implantation in uncontrolled glaucoma with at least a 6-month follow-up.
Nonrandomized, interventional, and retrospective clinical study. Failure was defined as IOP >21 mm Hg or less than 20% reduction of intraocular pressure (IOP) from baseline on 2 consecutive follow-up visits, IOP ≤5 mm Hg on 2 consecutive follow-up visits, reoperation of glaucoma or loss of light perception vision.
The mean preoperative IOP was 34.3±9.1 mm Hg, and the mean postoperative IOP at the last follow-up visit was 16.8±7.5 mm Hg with a pressure drop of 19.1±11.5 mm Hg (56%) (P=0.000; 95% CI 13.5-21.4). The Kaplan-Meier life-table analysis showed a 95% success rate after 6 months and a 71% success rate after 12 months of follow-up. Postoperative complications included cataract (6 eyes), choroidal detachment (3 eyes), flat anterior chamber (2 eyes), malignant glaucoma (2 eyes), encapsulated bleb (2 eyes), corneal decompensation (2 eyes), hyphaema (1 eye), uveitis (1 eye), retinal detachment (1 eye), suprachoroidal hemorrhage (1 eye), tube erosion (1 eye), and phthisis bulbi (1 eye).
The Molteno3 dual-chamber implant is useful and well tolerated in controlling IOP, but it does not seem to reduce the risk of postoperative hypotony.
评估 40 例连续患有未控制青光眼的 Molteno3 植入患者的治疗结果,随访时间至少 6 个月。
非随机、介入性、回顾性临床研究。失败定义为:2 次连续随访时眼压(IOP)>21mmHg 或与基线相比降低幅度<20%,2 次连续随访时IOP≤5mmHg,青光眼再次手术或光感丧失。
术前平均 IOP 为 34.3±9.1mmHg,末次随访时平均 IOP 为 16.8±7.5mmHg,眼压下降 19.1±11.5mmHg(56%)(P=0.000;95%CI 13.5-21.4)。Kaplan-Meier 生存表分析显示,术后 6 个月成功率为 95%,12 个月时成功率为 71%。术后并发症包括白内障(6 只眼)、脉络膜脱离(3 只眼)、浅前房(2 只眼)、恶性青光眼(2 只眼)、包裹性滤泡(2 只眼)、角膜失代偿(2 只眼)、前房积血(1 只眼)、虹膜炎(1 只眼)、视网膜脱离(1 只眼)、脉络膜下出血(1 只眼)、引流管侵蚀(1 只眼)和眼球萎缩(1 只眼)。
Molteno3 双腔植入物在控制眼压方面是有用且耐受良好的,但似乎不能降低术后低眼压的风险。